MAIA™ Platform

Impact

0+

Patient charts processed

0+

Clinical sites

0+

Clinical Trials

Problems We Solve

Enrollment bottlenecks

80% of clinical trials report enrollment issues, often due to prescreening constraints.

Scale requirements

Many trials require screening 10,000+ patients for eligibility, a task well suited to AI augmentation.

Rising complexity

With 43,677 new trials registered in 2024 and increasingly complex protocols, teams need AI to keep pace.

Case Study

An oncology site implements MAIA™ prescreening in February 2024

Full prescreening coverage

Moved from prescreening 250 out of 500 monthly patients to prescreening all incoming patients.

>80% enrollment lift

Enrollment increased by >80%, representing a ~$5M annual revenue lift.

Accuracy >95%

MAIA™ accuracy has been measured at >95%.

About Us

Our Vision

We aim to revolutionize healthcare through MAIA™, our flagship Medical AI Assistant, and a growing suite of applied solutions.

Our Values

Clinical AI is committed to delivering real value by addressing specific unmet needs. We believe in under-promising and over-delivering.